深圳瑞华泰薄膜科技股份有限公司 关于获得政府补助的公告 | 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-028 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 特此公告。 深圳瑞华泰薄膜科技股份有限公司董事会 2025 年 6 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得政府补助的基本情况 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）全资子公司嘉兴瑞 华泰薄膜技术有限公司于近日收到政府补助款人民币 3,189 万元，属于与资产相 关的政府补助。 二、补助的类型及对上市公司的影响 根据《企业会计准则第 16 号——政府补助》的有关规定，公司获得的上述 政府补助属于与资产相关的政府补助。上述政府补助未经审计，具体的会计处理 及对公司损益的影响最终以审计机构年度审计确认后的结果为准，敬请投资者注 意投资风险。 1 ...

Core Viewpoint - Hecotech Pharmaceuticals has received approval for its core product, Deutetrabenazine capsules, marking the company's first commercialized product after years of operating with zero drug revenue [2][3]. Group 1: Product Approval and Market Potential - Deutetrabenazine capsules are approved for treating metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have not previously received novel androgen receptor inhibitors [3]. - The drug is the first deuterated mechanism innovation in the prostate cancer field and the first domestic innovative drug approved for this indication [3]. - According to GLOBOCAN 2022, there were 1.467 million new prostate cancer cases globally in 2022, with 134,000 new cases reported in China [3]. Group 2: Company Financials and Historical Context - Prior to the approval of Deutetrabenazine, Hecotech Pharmaceuticals had maintained a "zero drug revenue" status, resulting in cumulative losses of 1.703 billion yuan from 2019 to 2024 [4]. - The company is accelerating its commercialization process and has established a GMP-compliant R&D production base in Chengdu, along with a professional marketing team [4]. Group 3: Competitive Landscape - Deutetrabenazine is a deuterated version of enzalutamide, which was originally developed by Astellas and Medivation and has generated over $4 billion in global sales by 2019 [5]. - Enzalutamide's sales reached $5.67 billion in 2024, making it a significant revenue source for Astellas [5]. - Several domestic companies have developed generic versions of enzalutamide, with competition expected to intensify as the patent expires in 2026 [5].

Investment Rating - The report maintains a "Recommended" rating for the chemical industry [1]. Core Insights - The report highlights the potential revaluation of phosphate rock value due to ongoing supply-demand tensions, with increasing demand for phosphate fertilizers and lithium iron phosphate batteries [6][4]. - The chemical industry is expected to enter a restocking cycle in 2025, driven by low inventory levels and improving profitability among leading chemical companies [5][27]. - The report emphasizes the expansion of phosphate production capacity by Batian Co., which is set to increase its phosphate rock extraction capacity to 2 million tons per year [4][6]. Summary by Sections Core Target Tracking - The report tracks key companies in the chemical sector, including Batian Co., which is expanding its phosphate production capacity significantly [4][6]. - It also notes the performance of various chemical products, with a focus on price increases for butadiene and polyester filament due to favorable market conditions [10][14]. Market Observation - The chemical sector has shown a relative performance of 6.7% over the past month, outperforming the CSI 300 index [2]. - The report indicates that the chemical industry is experiencing a recovery phase, with several companies poised for growth due to favorable market dynamics [5][27]. Data Tracking - The report provides detailed tracking of price movements for key chemical products, including butadiene, polyester filament, and various fertilizers, indicating a general upward trend in prices [10][12][17]. - It also highlights the current chemical industry sentiment index at 93.10, reflecting a positive outlook for the sector [6][33]. Investment Recommendations - The report suggests focusing on companies with low-cost expansion capabilities, such as Wanhua Chemical and various tire manufacturers, as well as those benefiting from rising product prices [5][7]. - It emphasizes the importance of high dividend yield companies in the chemical sector, particularly state-owned enterprises with stable financials [8][29].

Group 1 - The company will participate in the 2024 Annual Performance Presentation for the Advanced Petrochemical Chemical New Materials Industry on May 27, 2025, from 15:00 to 17:00 [2][3] - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [2][3] - Key personnel attending the meeting include the Vice Chairman and General Manager, Mr. Tang Changdan, Independent Director, Mr. Huang Hua, Chief Financial Officer, Mr. Huang Zehua, and Secretary of the Board, Ms. Li Tao [2] Group 2 - Investors can log in to the Shanghai Stock Exchange Roadshow Center to participate in the performance presentation and ask questions [3] - Questions can be submitted from May 20, 2025, to May 26, 2025, before 16:00 through the Roadshow Center website or via the company's email [3] - After the meeting, investors can view the presentation details and main content on the Shanghai Stock Exchange Roadshow Center [3]

| | | 深圳瑞华泰薄膜科技股份有限公司 关于参加 2024 年度先进石化化工新材料行业集体业 绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 27 日(星期二)下午 15:00-17:00 深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 22 日在上海证券交易所网站（http://www.sse.com.cn/）披露公司 2024 年年度报 告，为便于广大投资者更全面深入地了解公司 2024 年年度经营成果、财务状况， 公司计划于 2025 年 5 月 27 日(星期二)下午 15:00-17:00 参加 2024 年度科创板先 进石化化工新材料行业集体业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对 2024 年年度的经营 1 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

中国经济网北京5月9日讯瑞华泰(688323.SH)昨晚披露股东减持股份计划公告称，公司于近日收到股东 国投高科技投资有限公司(以下简称"国投高科")出具的《关于股份减持计划的告知函》。 因自身经营发展需要，公司股东国投高科拟通过集中竞价方式减持数量合计不超过1,800,002股(不超过 公司总股本比例1.0000%)。本次减持计划自公告披露之日起15个交易日之后的3个月内实施。上述股份 减持价格按市场价格确定。 | 股东名称 | 国投高科技投资有限公司 | | --- | --- | | 计划减持数量 | 不超过:1,800,002 股 | | 计划减持比例 | 不超过:1.0000% | | 减持方式及对应减持数量 | 集中竞价减持,不超过:1,800,002 股 | | 减持期间 | 2025年5月30日~2025年8月29日 | | 拟减持股份来源 | IPO 前取得 | | 拟减持原因 | 自身经营发展需要 | 瑞华泰上市发行费用为5033.09万元，其中保荐机构国信证券、联席主承销商中信建投证券获得保荐及 承销费用3420万元。 2022年9月9日，瑞华泰发布向不特定对象发行可转换公司债券上市公告 ...

Investment Announcements - Jinchengxin plans to invest approximately $231 million in the development of the Alacran copper-gold-silver mine project, aiming to acquire a 55% stake in CMH Colombia S.A.S. after the acquisition [3] - China Merchants Bank intends to invest 15 billion yuan to establish a wholly-owned financial asset investment company, enhancing its integrated financial services capabilities [5][6] Performance Reports - Huahong Semiconductor reported Q1 2025 revenue of 3.913 billion yuan, an 18.66% year-on-year increase, but net profit decreased by 89.73% to 22.76 million yuan due to uncertainties in the semiconductor industry [7] - King Long Motor's April bus sales were 3,611 units, a 3.91% year-on-year decrease, while production was 4,361 units, down 5.79% year-on-year [8] - Zhengbang Technology reported April sales of 609,800 pigs, with revenue of 738 million yuan, a 174.29% year-on-year increase, attributed to orderly resumption of production [9] - Sunac China achieved a contract sales amount of approximately 1.1 billion yuan in April, with a cumulative total of 11.2 billion yuan by the end of April [10] Major Contracts - Pinggao Electric won contracts totaling approximately 1.751 billion yuan from the State Grid, representing 14.12% of its 2024 revenue [13] - State Grid Information Technology's subsidiaries secured contracts worth 477 million yuan, positively impacting future operating performance [14] - Dongfang Iron Tower won contracts worth about 100 million yuan from the State Grid, accounting for 2.39% of its 2024 revenue [15] - Jiaojian Co. won a construction project worth approximately 704 million yuan, representing 8.43% of its 2024 revenue [16] Shareholding Changes - Ruihua Tai's shareholder plans to reduce holdings by up to 1% of the company's shares [17][18] - *ST Gengxing's controlling shareholder intends to increase holdings between 30 million and 60 million yuan [19] - Lexin Technology's shareholder plans to reduce holdings by up to 1.2032% of the company's shares [20] Share Buybacks - Sichuan Meifeng plans to repurchase shares worth 50 million to 70 million yuan, with a maximum buyback price of 10.07 yuan per share [21]

Investment Announcements - Jincheng intends to invest approximately $231 million in the Alacran copper-gold-silver mine project, following the acquisition of a 5% stake in CMH Colombia S.A.S., which will allow it to hold a 55% stake and control the project development [3] - Huasheng Technology's subsidiary plans to sell a 5.4019% stake in Shanghai Lingkai Technology Co., Ltd. for 200 million yuan, resulting in the subsidiary no longer holding shares in the company [4] - China Merchants Bank plans to invest 15 billion yuan to establish a wholly-owned financial asset investment company, which will enhance its integrated operations and service capabilities [5] Performance Reports - Huahong's Q1 revenue reached 3.913 billion yuan, a year-on-year increase of 18.66%, while net profit dropped by 89.73% to 22.76 million yuan, indicating challenges in the semiconductor industry due to international and policy changes [7] - King Long Automobile reported a production of 4,361 buses in April, a decrease of 5.79% year-on-year, with sales of 3,611 buses, down 3.91% [8] - Zhengbang Technology's April pig sales reached 609,800 heads, with revenue of 738 million yuan, showing a significant year-on-year increase of 174.29% [9] - Sunac China achieved a contract sales amount of approximately 1.1 billion yuan in April, with a cumulative total of 11.2 billion yuan by the end of April [11] - *ST Aonong reported a pig sales volume of 132,800 heads in April, a year-on-year decrease of 14.42% [12] Major Contracts - Pinggao Electric won contracts totaling approximately 1.751 billion yuan from the State Grid, representing 14.12% of its 2024 revenue [14] - State Grid Information Technology's subsidiaries secured contracts worth 477 million yuan, positively impacting future performance [15] - Dongfang Tower won a procurement project from the State Grid worth about 100 million yuan, accounting for 2.39% of its 2024 revenue [16] - Jiaojian Co. won a construction project worth approximately 704 million yuan, with a project duration of 870 days, representing 8.43% of its 2024 revenue [17] Shareholding Changes - Ruihua Tai's shareholder plans to reduce holdings by up to 1% of the company's shares [19] - *ST Gengxing's controlling shareholder intends to increase holdings between 30 million and 60 million yuan [20] - Lexin Technology's shareholder plans to reduce holdings by up to 1.2032% of the company's shares [22] Share Buybacks - Sichuan Meifeng plans to repurchase shares worth between 50 million and 70 million yuan, with a maximum repurchase price of 10.07 yuan per share [24]

| 证券代码：688323 | 证券简称：瑞华泰 | 公告编号：2025-026 | | --- | --- | --- | | 转债代码：118018 | 转债简称：瑞科转债 | | 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，国投高科技投资有限公司（以下简称"国投高科"）持 有深圳瑞华泰薄膜科技股份有限公司（以下简称"公司"）20,466,447 股股份， 占公司总股本的 11.3702%。以上股份为首次公开发行前取得的股份，且已于 2024 年 4 月 29 日起解除限售并上市流通。 减持计划的主要内容 国投高科拟通过集中竞价方式减持数量合计不超过 1,800,002 股（不超过公 司总股本比例 1.0000%）。本次减持计划自本公告披露之日起 15 个交易日之后的 3 个月内实施。 上述股份减持价格按市场价格确定，若减持期间公司有派息、送股、资本公 积金转增股本、配股等除权除息事项，减持计划将进行相应调整。 公司于近日收到 ...